3544.T

The company's capital structure is characterized by a debt-to-equity ratio of 1.76, indicating a relatively high reliance on debt financing. Its liquidity position is moderate, with a current ratio of 1.13 and cash and equivalents amounting to 2.67 billion JPY, which is insufficient to cover its long-term debt of 17.21 billion JPY. The price-to-book ratio of 1.16 suggests that the market values the company slightly above its book value.

Profitability metrics show a return on equity of 7.85% and a return on assets of 1.66%, both of which are below the typical thresholds for high-performing retailers in the industry. The operating margin, calculated as operating income of 1.25 billion JPY on revenue of 100.17 billion JPY, is 1.24%, which is relatively low compared to industry benchmarks. The company's gross margin of 25.59% is in line with the industry average, but the low operating margin suggests significant operating expenses.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with market-specific downturns. The company's revenue is entirely derived from its core drug retailing operations, with no material contributions from other segments.

The company's growth trajectory is modest, with a current FY revenue of 100.17 billion JPY and a net income of 769 million JPY. The next FY outlook is not explicitly provided, but the company's operating cash flow of 2.60 billion JPY and free cash flow of 204 million JPY suggest limited capacity for significant expansion. The company's capital expenditure of 1.83 billion JPY indicates ongoing investment in infrastructure, but the scale is relatively small compared to its total assets.

The company faces moderate liquidity risk, as its cash and equivalents are insufficient to cover its long-term debt obligations. The risk assessment indicates a medium liquidity risk, with a key flag noting that net cash is negative after subtracting total debt. The dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. The company's valuation adjustments do not indicate any material dilution pressures.

Recent events and filings do not provide specific details on new product launches or strategic initiatives. The company's latest actual EPS of 34.07 JPY and revenue of 95.52 billion JPY align with its reported financials, suggesting stable performance. No recent transcripts or filings indicate significant changes in the company's strategic direction or operational performance.